Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dubermatinib (TP-0903) in Previously Treated CLL/SLL
NCT03572634Phase 2Terminated
- Sponsor
- Sumitomo Pharma America
- Start
- Jun 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dubermatinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by Sumitomo Pharma America. Primary endpoints: Incidence of Dose-limiting Toxicities at 28 days, Treatment Emergent Adverse Events at 28 days and 1 more. Started Jun 2019; status: terminated.
02
Drugs
dubermatinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03572634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03572634.